The Medical Letter on Drugs and Therapeutics
Ixekizumab (Taltz) - A Second IL-17A Inhibitor for Psoriasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved ixekizumab (Taltz – Lilly), an injectable humanized interleukin (IL)-17A antagonist, for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ixekizumab is the second IL-17A antagonist to be approved for this indication in the US; secukinumab (Cosentyx – Novartis) was the first.1

STANDARD TREATMENT — Psoriasis is a chronic inflammatory, immune-mediated condition associated with multiple comorbidities. Mild to moderate psoriasis is generally treated with topical corticosteroids. Topical vitamin D analogs and the retinoid tazarotene (Tazorac) are alternatives that can be used alone or in combination with topical corticosteroids.2 UVB phototherapy can be used for treatment of widespread or unresponsive disease. For patients ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ixekizumab (Taltz) - A Second IL-17A Inhibitor for Psoriasis
Article code: 1494b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian